European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
European Journal of Cancer · 2023-10 · 192 · 113254
DOI: 10.1016/j.ejca.2023.113254 ↗Kurz gefasst
Leitlinie in der Zeitschrift European Journal of Cancer, 2023-10. Verfasst von Ketty Peris und 32 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. …. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Skin Neoplasms. Die Arbeit wurde bisher 307-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology (ESTRO), Union Européenne des Médecins Spécialistes, and the European Academy of Dermatology and Venereology developed updated recommendations on diagnosis and treatment of BCC. BCCs were categorised into 'easy-to-treat' (common) and 'difficult-to-treat' according to the new EADO clinical classification. Diagnosis is based on clinico-dermatoscopic features, although histopathological confirmation is mandatory in equivocal lesions. The first-line treatment of BCC is complete surgery. Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs. Management of 'difficult-to-treat' BCCs should be discussed by a multidisciplinary tumour board. Hedgehog inhibitors (HHIs), vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCC. Immunotherapy with anti-PD1 antibodies (cemiplimab) is a second-line treatment in patients with a progression of disease, contraindication, or intolerance to HHI therapy. Radiotherapy represents a valid alternative in patients who are not candidates for or decline surgery, especially elderly patients. Electrochemotherapy may be offered when surgery or radiotherapy is contraindicated. In Gorlin patients, regular skin examinations are required to diagnose and treat BCCs at an early stage. Long-term follow-up is recommended in patients with high-risk BCC, multiple BCCs, and Gorlin syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. Electronic address: ketty.peris@unicatt.it.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
- Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Germany.
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- Department of Oncology, Odense University Hospital, Denmark.
- Dermatology Department, Saint-Louis Hospital, Paris, France.
Zitieren
APA
Peris, K., Fargnoli, M. C., Kaufmann, R., Arenberger, P., Bastholt, L., Seguin, N. B., Bataille, V., Brochez, L., Del Marmol, V., Dummer, R., Forsea, A. M., Gaudy-Marqueste, C., Harwood, C. A., Hauschild, A., Höller, C., Kandolf, L., Kellerners-Smeets, N. W. J., Lallas, A., Leiter, U., …, & EADO”A, EDF”B, ESTRO”C, UEMS”D and EADV”E (2023). European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023. European Journal of Cancer, 192, 113254. https://doi.org/10.1016/j.ejca.2023.113254
Vancouver
Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023. European Journal of Cancer. 2023;192:113254. doi:10.1016/j.ejca.2023.113254
BibTeX
@article{Peris2023,
author = {Peris, Ketty and Fargnoli, Maria Concetta and Kaufmann, Roland and Arenberger, Petr and Bastholt, Lars and Seguin, Nicole Basset and Bataille, Veronique and Brochez, Lieve and Del Marmol, Veronique and Dummer, Reinhard and Forsea, Ana-Marie and Gaudy-Marqueste, Caroline and Harwood, Catherine A and Hauschild, Axel and Höller, Christoph and Kandolf, Lidija and Kellerners-Smeets, Nicole W J and Lallas, Aimilios and Leiter, Ulrike and Malvehy, Josep and Marinović, Branka and Mijuskovic, Zeljko and Moreno-Ramirez, David and Nagore, Eduardo and Nathan, Paul and Stratigos, Alexander J and Stockfleth, Eggert and Tagliaferri, Luca and Trakatelli, Myrto and Vieira, Ricardo and Zalaudek, Iris and Garbe, Claus and EADO”A, EDF”B, ESTRO”C, UEMS”D and EADV”E, EADO”A, EDF”B, ESTRO”C, UEMS”D and EADV”E},
title = {European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023},
journal = {European Journal of Cancer},
year = {2023},
volume = {192},
pages = {113254},
doi = {10.1016/j.ejca.2023.113254}
}
EUVIMED